Compare Globalstar (GSAT) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globalstar vs Illumina, Inc. — how do they compare? Globalstar trades at $82.03 (market cap $10.69B), while Illumina, Inc. trades at $207.78 (market cap $31.17B). The key difference: Illumina, Inc. is far larger — about 2.9× Globalstar's market cap, and Globalstar is trading nearer its 52-week high, Illumina, Inc. nearer its low. Which is the better fit depends on your goals.
| GSAT | ILMN | |
|---|---|---|
Market Cap | $10.69B | $31.17B |
Sector | Technology | Health |
52-Week High | $84.43 | $227.69 |
52-Week Low | $29.94 | $91.00 |
Enterprise Value | $10.69B | $32.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Illumina (ILMN) trades at $206.45, up 2.57% today, near its consensus price target of $208.14. The stock shows a bearish technical signal but strong fundamentals, with three consecutive quarterly EPS beats and a significant turnaround to a net income of $850 million in 2025. Recent news highlights its upcoming inclusion in the S&P 500 index in September 2026, which may attract institutional interest.
The outlook is cautiously optimistic. Robust profitability and positive earnings momentum support upside potential, but high valuation multiples and bearish technical indicators present near-term risks. Investor sentiment is mixed, with analysts predominantly bullish but technicals suggesting caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Globalstar
Globalstar provides satellite and terrestrial connectivity services, including voice, data, asset tracking, and private wireless solutions. It operates a low-Earth-orbit satellite network and holds licensed mid-band spectrum.
Read more on GSAT →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
